Unichem Laboratories gained 1.15% to Rs 280.85 after the company said it received US drug regulator s approval for celecoxib capsules, an anti-inflammatory drug.
In a regulatory filing made during market hours today, the company said that it had received ANDA approval for its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg from the United States Food and Drug Administration (US FDA). The product is a generic version of Celebrex capsules of G.D. Searle LLC, Division of Pfizer Inc.
Celecoxib capsules are indicated for treatment of osteoarthritis, rheumatoid arthritis juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain and primary dysmenorrhea. The product will be commercialized from Unichem s Goa Plant, the company said in a statement.
Key equity barometers hit fresh intraday low as selling intensified in mid-afternoon trade. At 14:24 IST, the barometer index, the S&P BSE Sensex, was down 233.96 points or 0.47% to 49,283.15. The Nifty 50 index lost 66.70 points or 0.46% to 14,496.75.
Investors continued to monitor the developments on the US political front as the US House of Representatives is expected to vote on an impeachment motion against President Trump today.
The broader market underperformed the benchmark indices. The S&P BSE Mid-Cap index fell 1.13%. The S&P BSE Small-Cap index slipped 0.79%.
Sellers outpaced buyers. On the BSE, 1051 shares rose and 1957 shares fell. A total of 149 shares were unchanged.